Fundz

AEON Biopharma raised $15M in a private placement of senior secured convertible notes led by Daewoong Pharmaceutical Co., LTD to support late-stage clinical development of ABP-450 and for general working capital purposes.

PRIVATEMar 21, 2024

Amount Raised

$15 Million

Round Type

Convertible Note

IrvineBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Investors

Daewoong Pharmaceutical Co., Ltd.

Description

AEON Biopharma announced a $15 million private placement of senior secured convertible notes with Daewoong Pharmaceutical Co., LTD. The funds are to be used to support the late-stage clinical development of ABP-450 and for general working capital purposes, following the termination of forward purchase agreements to simplify the capitalization structure.

Quick answer

AEON Biopharma raised $15 Million in a Convertible Note round, dated March 21, 2024. Investors: Daewoong Pharmaceutical Co., Ltd. AEON Biopharma is based in Irvine, California, United States.

How much did AEON Biopharma raise?
AEON Biopharma raised $15 Million in a Convertible Note round on March 21, 2024.
Who invested in AEON Biopharma?
Daewoong Pharmaceutical Co., Ltd. is named as investors in this round.
What does AEON Biopharma do?
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial..
Where is AEON Biopharma based and how big is it?
AEON Biopharma is based in Irvine, California, United States.
Who are the decision-makers at AEON Biopharma?
Fundz holds 1 contact at AEON Biopharma. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as AEON Biopharma that raised within 45 days of this round, from Fundz verified event records.

  • BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
  • Crinetics Pharmaceuticals raised $350M on March 1, 2024.
  • Parabilis Medicines raised $145M (Series E) on March 1, 2024.
  • vTv Therapeutics Inc. raised $51M on February 27, 2024.
  • Ajax Therapeutics, Inc. raised $95M on April 26, 2024.
  • TORL BioTherapeutics raised $158M (Series B) on April 10, 2024.

Who to call at AEON Biopharma, and when

A new round usually means AEON Biopharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AEON Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AEON Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AEON Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AEON Biopharma

Location

5 PARK PLAZA

Irvine, California, United States

About

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AEON Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AEON Biopharma's next move

See what Strategic adds

AEON Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.